2.

TKI联合放疗治疗NSCLC的临床研究结果

Clinical trials on TKI combined with radiation treatment for NSCLCs

Reference	Study type	Patients	RT schedule	Systemic therapy	Result	Survival (month）
Md PFS: median progress free survival; NSqCLC: non-squamous cell, non-small cell lung cancer; LCR: local control rate; *: no apparent survival difference with EGFR-activating mutations versus wild type.
Chang CC. et al [27]	Retrospective Single institution (n=25)	NSqCLC stage Ⅲb or Ⅳ responded to TKI	Hypofractionated RT 40 Gy-50 Gy /16 f-20 f	With TKI	RR (%): 84.0	Md PFS: 16.0
Zeng YD. et al [28]	Retrospective Single institution (n=90)	NSCLC with brain metastases	With or without concomitant WBRT	With TKI	RR (%): RT+TKI 64.4 TKI 26.7 P < 0.001	Md OS: RT+TKI 23.4 TKI 14.8
Wang J. et al [29]	Prospective Single institution (n=25)	NSCLC stage Ⅲb or Ⅳ	Curative RT: 66 Gy/33 f	With TKI	LCR (%): 96.0	Md PFS 10.2 Md OS 21.8
Ready N. et al [31]	Prospective Single institution (n=60)	NSCLC stage Ⅲ	Curative RT: 66 Gy/33 f Poor-risk: concomitant RT Good-risk: concurrent CRT	2 cycle introduction chemotherapy followed by TKI	RR (%): RT+TKI 52.4 CRT+TKI 81.6	*Md PFS: RT+TKI 13.4 CRT+TKI 9.2 *Md OS: RT+TKI 19.0 CRT+TKI 13.0